Member Info for CHELSEA7

All Buys Latest Trades Date & Time Volume Price 26/04/2018 10:10 10,000 11.88 26/04/2018 09:51 5,000 11.88 26/04/2018 09:37 5,000 11.94

Well that"s 4950 for me. Now back to waiting, lol.

That"s my hope keiny. TBH the trades have little meaning at the moment. As we have seen in the past few months things change very quickly on AIM. Back to waiting for us!!

Just one MM left on it, was four on Monday.

Unfortunately not rats, RNS service is back on though.

The RNSs feed isn"t working!!!

Wassat, yeah. last Monday. You next buddy, thanks very much..........................

My 05.39 question touched on that. We seem to be doing a heck of a lot in this area.

NEX 25/04/2018 13:21 49,900 12.08 Ask could have bottomed out.

12-12.30

Prof Michael Platten https://www.dkfz.de/en/neuroimmunologie/index.php Prof Hans-George Rammensee https://www.dkfz.de/en/neuroimmunologie/index.php Prof Ugur Sahin https://www.dkfz.de/en/neuroimmunologie/index.php Prof Jolande deVries https://www.dkfz.de/en/neuroimmunologie/index.php Prof Panduragan Vijayanand http://www.lji.org/faculty-staff/pandurangan-vijayanand/ Sjoerd van der Berg https://www.universiteitleiden.nl/en/staffmembers/sjoerd-van-der-burg#tab-1 Jedd Wolchock https://www.mskcc.org/cancer-care/doctors/jedd-wolchok Posted by Goosed on Advfn

Cruk Grand Challenge Blueprint Team http://www.cancerresearchuk.org/funding-for-researchers/how-we-deliver-research/grand-challenge-award/shortlistedteamdurrant Prof Vinod Balacharon https://www.mskcc.org/cancer-care/doctors/vinod-balachandran Dr Adam Benhan https://www.dur.ac.uk/biosciences/about/schoolstaff/profile/?id=5 Prof Vincenzo Cerundolo http://www.ludwig.ox.ac.uk/vincenzo-cerundolo-group-page Prof Dirk Jaeger https://www.nct-heidelberg.de/en/the-nct/organization/directorate/prof-dr-dirk-jaeger.html Prof Hisham Mehanna https://www.nct-heidelberg.de/en/the-nct/organization/directorate/prof-dr-dirk-jaeger.html Prof Cornelus Melief https://www.nct-heidelberg.de/en/the-nct/organization/directorate/prof-dr-dirk-jaeger.html Prof Ira Mellman https://www.gene.com/scientists/our-scientists/ira-mellman Prof Christian Ottesheimer http://www.uhs.nhs.uk/ClinicalResearchinSouthampton/Our-people/Directors/Prof-Christian-Ottensmeier-director-NIHR-CRUK-Experimental-Cancer-Medicine-Centre.aspx

Well done Minor.

40k Tick Up 12/12.40

Here on LSE again, taking ages to get the page up. Lets hope it is fixed quickly it has been months now.

Yeah, well done last night. Mourinho, the manager who sold Lukaku, Salah and de Bruyne!!! LOL X

Thanks buddy, and it"t true.

Very good point..........................""" JC has his 2 million cheap shares now so hopefully next stage that commercial action we have been told to expect.""" .. Indeed Chiplin has backed both placings......................if it"s good enough for him.....................................

Is the amount of work we are doing with antibodies beyond the norm of existing treatments on the market?? Advances in understanding the pattern of sugars (glycans) that adorn cells have highlighted important differences between those on tumour cells versus their normal counterparts. This altered sugar signature of tumour cells is intricately linked to the majority of cancer cell biology hallmarks. Antibodies that target such tumour glycan signatures, when coupled to a novel approach to invoke an immune response on binding, provide an attractive strategy for immunotherapy and forms the basis of the platform technology developed by Prof. Lindy Durrant and her team at the Nottingham University Therapeutic Antibody Centre (NUTAC).1

http://www.lse.co.uk/share-regulatory-news.asp?shareprice=SCLP&ArticleCode=4e38g2pd&ArticleHeadline=Proposed_Placing_Subscription_and_Open_Offer Additional funding could be provided either by a commercial agreement with a development partner, such as a large pharmaceutical company, or by further equity issuance to existing and/or new Shareholders. The Directors believe that delivering the milestones outlined above will enhance the value of the Company and prepare it for further later stage fundraising. The Directors also believe that these milestones will ensure wider recognition of the Company both in the US and Europe for the quality and value of both the ImmunoBody� and Moditope� platforms.